Evaluation of a monoclonal IgM antibody for purging of bone marrow for autologous transplantation.
A monoclonal antibody of the IgM class, reacting with the CD9 (p24) antigen is described. The antibody (FMC27) is cytotoxic against cells of the common type of acute lymphoblastic leukaemia (c-ALL), giving killing at higher dilutions than an IgG antibody (FMC8) against the same antigen. FMC27 and FMC8 recognise different epitopes, and FMC27 may thus be used in a cocktail together with FMC8 and an antibody against the c-ALL antigen, WM21. Furthermore, the IgM antibody can be coated directly onto magnetic microparticles for magnetic purging, unlike the IgG antibody which must be used in a two-layer procedure.
Zola
H
H
Department of Clinical Immunology, Flinders Medical Centre, Bedford Park, Australia.
Potter
A
A
Neoh
S H
SH
Juttner
C A
CA
Haylock
D N
DN
Rice
A M
AM
Favaloro
E J
EJ
Kabral
A
A
Bradstock
K F
KF
D000911:Antibodies, Monoclonal / Q000627:therapeutic use* / Q000633:toxicity; D000937:Antigen-Antibody Reactions; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000276:immunology; D000961:Antilymphocyte Serum / Q000633:toxicity; D001853:Bone Marrow / Q000276:immunology*; D016026:Bone Marrow Transplantation; D002460:Cell Line; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D007075:Immunoglobulin M / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000473:pathology / Q000628:therapy; D008212:Lymphocyte Depletion; D008562:Membrane Glycoproteins; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D060245:Tetraspanin 29; D014182:Transplantation, Autologous / Q000379:methods
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D000961:Antilymphocyte Serum; C554869:CD9 protein, human; D007075:Immunoglobulin M; D008562:Membrane Glycoproteins; D060245:Tetraspanin 29